Four takeaways from the company’s financial report:
1. Revenue in the second quarter was $434.8 million, up 62 percent from the same period last year.
2. Net loss was $176.92 million, or $1.03 per share.
3. Screening revenue, which includes Cologuard tests, increased 101 percent to$263.9 million.
4. Precision oncology revenue was $137.8 million, a 34 percent increase compared to the same time last year. COVID-19 testing revenue was $33.1 million, down 4 percent for the same period.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
